Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME-RT: Durvalumab in Rectal Cancer
NCT04621370Phase 2Not yet recruiting
- Sponsor
- Liz-Anne Lewsley
- Start
- Dec 2020
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
Phase 2, randomised, open-label trial of durvalumab in rectal cancer (2 arms), sponsored by Liz-Anne Lewsley. Primary endpoint: Complete response at 6 months. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04621370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621370.